Inactive Instrument

Centrexion Therapeutics Corporation

CNTX

US15643W1009

Biotechnology & Medical Research

Centrexion Therapeutics Corporation announced that it has received $16.475 million in funding

June 07, 2022

As of June 8, 2022, the company has received $62,500 in its first tranche. The transaction included participation from 25 investors.

Latest news about Centrexion Therapeutics Corporation

Centrexion Therapeutics Corp. announced a financing transaction	12-27	CI
Centrexion Therapeutics Corporation announced that it has received $2.3 million in funding	11-26	CI
Centrexion Therapeutics Corporation announced that it expects to receive $2.3 million in funding	11-13	CI
Centrexion Therapeutics Corporation announces tranche update	23-07-10	CI
Centrexion Therapeutics Corporation announced a financing transaction	23-06-13	CI
Centrexion Therapeutics Corporation announced that it has received $29.14 million in funding	22-08-10	CI
Centrexion Therapeutics Corporation announced that it has received $16.475 million in funding	22-06-07	CI
Centrexion Therapeutics Corporation announced that it expects to receive $16.475 million in funding	22-05-23	CI
Earnings Flash (CNTX) CONTEXT THERAPEUTICS Posts Q1 Loss $-0.22	22-05-11	MT
HC Wainwright Starts Context Therapeutics at Buy With $6 Price Target	22-02-02	MT
ThinkEquity Starts Context Therapeutics at Buy with $10 Price Target	22-01-24	MT
Health Care Stocks Staying On Positive Ground in Late Trade	21-12-10	MT
Health Care Stocks Hanging On For Slim Gains	21-12-10	MT
Wall Street Sees Upbeat Open, US CPI Rises More Than Expected	21-12-10	MT
Top Premarket Gainers	21-12-10	MT
Context Therapeutics Says Drug Candidate Decreased Reproduction of Breast Cancer Tumor Cells in Open-Label Trial; Shares Rise Pre-Bell	21-12-10	MT
Context Therapeutics Closes $31.3 Million Private Placement of Common Shares, Warrants; Shares Up After Hours	21-12-06	MT
Context Therapeutics Q3 Net Loss Widens	21-12-02	MT
Earnings Flash (CNTX) CONTEXT THERAPEUTICS Reports Q3 Loss $-4.00	21-12-02	MT
Health Care Stocks Trailing Thursday Field Higher	21-12-02	MT
Sector Update: Health Care	21-12-02	MT
Top Midday Decliners	21-12-02	MT
Context Therapeutics Expects to Raise $31.3 Million in Private Placement of Common Shares, Warrants	21-12-02	MT
Context Therapeutics Names Jennifer Minai-Azary Chief Financial Officer	21-11-01	MT
Centrexion Therapeutics : Context Therapeutics Closes $28.8 Million IPO	21-10-22	MT

Chart Centrexion Therapeutics Corporation

Duration

Period

Chart Centrexion Therapeutics Corporation

More charts

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research